{"id":681959,"date":"2026-03-26T00:49:18","date_gmt":"2026-03-26T00:49:18","guid":{"rendered":"https:\/\/www.europesays.com\/us\/681959\/"},"modified":"2026-03-26T00:49:18","modified_gmt":"2026-03-26T00:49:18","slug":"does-weight-loss-medication-improve-fitness","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/us\/681959\/","title":{"rendered":"Does Weight Loss Medication Improve Fitness?"},"content":{"rendered":"<p>Losing weight doesn\u2019t necessarily make you fitter, a new study finds.<\/p>\n<p><img alt=\"woman running on rocky singltrack in red jacket\" src=\"https:\/\/cdn.outsideonline.com\/wp-content\/uploads\/2026\/03\/woman-running.jpg\" data-loaded=\"true\" fetchpriority=\"high\" loading=\"eager\" width=\"2400\" height=\"1350\" decoding=\"async\" data-nimg=\"1\" style=\"color:transparent\"  bad-src=\"https:\/\/www.europesays.com\/us\/wp-content\/uploads\/2026\/03\/woman-running.jpg\"\/><\/p>\n<p class=\"fp-leadCaption py-tight text-left font-utility text-utility3-size leading-utility3-line-height text-secondary\"> (Photo: Oleg Breslavtsev \/ Getty)<\/p>\n<p>Published March 25, 2026 12:36PM<\/p>\n<p>Is exercise obsolete in the age of Ozempic? Now that the initial hype has settled down, nobody makes that claim with a straight face. In fact, one of the big fears among people taking GLP-1 agonists (the class of drug to which Ozempic belongs) is that they\u2019ll lose too much muscle along with all the fat, leaving them weaker and less healthy. But at this point, there\u2019s very little data on what happens when you combine these drugs with an exercise routine (or lack thereof).<\/p>\n<p>A <a target=\"_blank\" class=\"text-brand-primary underline hover:text-brand-primary\/85 break-words overflow-wrap-anywhere underline-offset-[3px]\" data-afl-p=\"0\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/41579235\/\" rel=\"nofollow noopener\">newly published study<\/a> in the journal Sports Medicine steps into this gap. It\u2019s a secondary analysis of data from a previously published study by researchers at the University of Copenhagen in Denmark, funded in part by the Novo Nordisk Foundation (Novo Nordisk is the company that makes Ozempic). The study follows volunteers taking another Novo Nordisk GLP-1 agonist called liraglutide (sold under the brand names Victoza and Saxenda) for an entire year, with or without the addition of a regular exercise program. The results show that without exercise, both health and physical function suffer\u2014and it\u2019s not just about muscle.<\/p>\n<p>What the GLP-1 Study Found<\/p>\n<p>The study involved 193 adults between the ages of 18 and 65. It\u2019s a little unusual in that they started by following an eight-week very-low-calorie diet before starting either exercise or the GLP-1 drug. That\u2019s because the original study was designed to look at ways of maintaining weight loss. Everyone included in the study lost at least 5 percent of their starting weight, which resulted in an average weight loss of 29 pounds. Then, for the following year, they either exercised, took the GLP-1 drug, did both, or did neither. (Those who didn\u2019t get the drug got a placebo.)<\/p>\n<p>The exercise program involved two group exercise classes per week, including 30 minutes of intervals on an exercise bike, then 15 minutes of circuit training (step-ups, boxing, squats, kettlebells, and so on). The subjects were also asked to do two additional workouts on their own; the details were up to them, but most chose running, cycling, brisk walking, or circuits. Adherence was decent: they averaged 2.65 workouts a week and met standard public health guidelines for physical activity.<\/p>\n<p>The first outcome of interest (as reported in <a target=\"_blank\" class=\"text-brand-primary underline hover:text-brand-primary\/85 break-words overflow-wrap-anywhere underline-offset-[3px]\" data-afl-p=\"0\" href=\"https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2028198\" rel=\"nofollow noopener\">the original analysis<\/a>) is weight. Here\u2019s the trajectory of the four groups:<\/p>\n<p><img alt=\"Graphing showing that the combination of exercise and a GLP-1 drug was most effective for maintaining weight loss.\" loading=\"lazy\" width=\"2400\" height=\"1350\" decoding=\"async\" data-nimg=\"1\" class=\"aligncenter size-full wp-image-2736306\" style=\"color:transparent\"  src=\"https:\/\/www.europesays.com\/us\/wp-content\/uploads\/2026\/03\/low-cal.jpg\"\/>The combination of exercise and a GLP-1 drug was most effective for maintaining weight loss. (Photo: Sports Medicine)<\/p>\n<p>Doing nothing was the worst option. Exercising and taking a GLP-1 drug was the best option. If you had to choose one or the other, the drug looks marginally better, though the difference wasn\u2019t statistically significant.<\/p>\n<p>Does Fitness or Fatness Matter More?<\/p>\n<p>There\u2019s a longstanding debate about the relative health effects of being overweight versus being aerobically unfit. The two often go together, so they get conflated\u2014but they\u2019re not the same thing. The general trend of evidence, according to the Danish research team, is that it\u2019s better for health and longevity to be fit and overweight than unfit and normal weight. This distinction is important in the context of GLP-1 drugs, because if they help you lose weight without gaining fitness, then the health benefits may be less than you\u2019d expect.<\/p>\n<p>Figuring out how to measure fitness in this context isn\u2019t straightforward. When you lose weight, you\u2019ll generally lose some muscle mass in addition to fat loss. Both strength and aerobic fitness (as measured by <a target=\"_self\" class=\"text-brand-primary underline hover:text-brand-primary\/85 break-words overflow-wrap-anywhere underline-offset-[3px]\" data-afl-p=\"0\" href=\"https:\/\/www.outsideonline.com\/health\/training-performance\/vo2-max-just-turned-100-heres-what-it-means\/\" rel=\"nofollow noopener\">VO2 max<\/a>) are roughly proportional to muscle mass, so your absolute fitness might appear to decline when you lose a lot of weight. But if you lose less strength or fitness in proportion to your overall weight loss, you\u2019ll still end up with greater functional fitness: you\u2019ll have an easier time getting up from a chair, be able to walk for longer, and so on.<\/p>\n<p>One of the simple functional tests the Danish study included was a stair-climb test: climb up and down an 11-step stairway twice, as fast as possible. Here\u2019s what those results looked like:<\/p>\n<p><img alt=\"Graphing showing that the key to climbing stairs more quickly was exercise, with or without a GLP-1 drug.\" loading=\"lazy\" width=\"2400\" height=\"1350\" decoding=\"async\" data-nimg=\"1\" class=\"aligncenter size-full wp-image-2736308\" style=\"color:transparent\"  src=\"https:\/\/www.europesays.com\/us\/wp-content\/uploads\/2026\/03\/stair.jpg\"\/>The key to climbing stairs more quickly was exercise, with or without a GLP-1 drug. (Photo: Sports Medicine)<\/p>\n<p>It\u2019s clear here that the exercise program helped people speed up and down the stairs more quickly, whether or not they were taking the GLP-1 drug. Just taking the drug without exercising didn\u2019t have any benefit.<\/p>\n<p>There are a whole bunch of other fitness measures in the paper: VO2 max tests, leg strength tests, body composition tests to measure muscle mass in the arms and legs. The fitness outcomes can be expressed in absolute terms, or relative to total body weight, or relative to muscle mass. No matter how you express it, the overall pattern, with a few minor exceptions, is the same as the graph above: exercise makes you fitter, simply taking the drug doesn\u2019t.<\/p>\n<p>(An example of a minor exception: the drug alone was enough to improve relative leg strength, i.e. leg strength divided by total body weight, because weight decreased more than strength. But adding exercise worked even better.)<\/p>\n<p>This conclusion\u2014that the best way to get fitter is to exercise\u2014is not exactly surprising. But I think it has been overlooked in discussions about GLP-1 drugs. I\u2019ve certainly seen lots of chatter about <a target=\"_blank\" class=\"text-brand-primary underline hover:text-brand-primary\/85 break-words overflow-wrap-anywhere underline-offset-[3px]\" data-afl-p=\"0\" href=\"https:\/\/www.nytimes.com\/2024\/02\/08\/well\/live\/ozempic-muscle-loss-exercise.html\" rel=\"nofollow noopener\">the dangers of muscle loss with Ozempic<\/a>, and the need to pound protein and lift weights. That\u2019s a legitimate concern, but aerobic fitness is an even better <a target=\"_blank\" class=\"text-brand-primary underline hover:text-brand-primary\/85 break-words overflow-wrap-anywhere underline-offset-[3px]\" data-afl-p=\"0\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/29293447\/\" rel=\"nofollow noopener\">predictor of longevity<\/a> and marker of general health. GLP-1 drugs have remarkable properties, but they haven\u2019t made exercise obsolete.<\/p>\n<p>For more Sweat Science, sign up for the <a target=\"_blank\" class=\"text-brand-primary underline hover:text-brand-primary\/85 break-words overflow-wrap-anywhere underline-offset-[3px]\" data-afl-p=\"0\" href=\"https:\/\/sweatscience.substack.com\/\" rel=\"nofollow noopener\">email newsletter<\/a> and check out my new book <a target=\"_blank\" class=\"text-brand-primary underline hover:text-brand-primary\/85 break-words overflow-wrap-anywhere underline-offset-[3px]\" rel=\"nofollow noopener\" data-afl-p=\"0\" href=\"https:\/\/www.amazon.com\/Explorers-Gene-Challenges-Flavors-Blank\/dp\/0063269767\/\">The Explorer\u2019s Gene: Why We Seek Big Challenges, New Flavors, and the Blank Spots on the Map<\/a>.<\/p>\n<p>\u00a0<\/p>\n","protected":false},"excerpt":{"rendered":"Losing weight doesn\u2019t necessarily make you fitter, a new study finds. (Photo: Oleg Breslavtsev \/ Getty) Published March&hellip;\n","protected":false},"author":3,"featured_media":681960,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[38],"tags":[226279,103932,1198,210,149997,109010,286608,184545,97600,67,132,68],"class_list":{"0":"post-681959","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-fitness","8":"tag-audio-true","9":"tag-editor-awise","10":"tag-fitness","11":"tag-health","12":"tag-parent_category-health","13":"tag-tag-evergreen","14":"tag-tag-glp-1s","15":"tag-tag-sweat-science","16":"tag-type-article","17":"tag-united-states","18":"tag-unitedstates","19":"tag-us"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@us\/116292732087700042","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/681959","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/comments?post=681959"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/681959\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media\/681960"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media?parent=681959"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/categories?post=681959"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/tags?post=681959"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}